Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2017 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Third Quarter 2017 Financial Results

BERKELEY, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the third quarter of 2017. Net loss for the third quarter of 2017 was $24.5...
October 17, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer

BERKELEY, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that its license...
October 09, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer’s 32nd Annual Meeting

BERKELEY, Calif., Oct. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced data presentations...
September 27, 2017 08:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Personalized Immunotherapy pLADD Based on Proprietary Neoantigen Technology

BERKELEY, Calif., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the first...
September 26, 2017 08:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Announces Advancement of ADU-S100 into Global Combination Trial With PDR001 for the Treatment of Solid Tumors and Lymphomas

BERKELEY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, announced today that the first...
September 18, 2017 16:02 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at Three Investor Conferences in the Second Half of September

BERKELEY, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at three investor conferences in New York, NY in the second...
August 31, 2017 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at Three Investor Conferences in the First Half of September

BERKELEY, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Aduro management will present at the following investor conferences in New York, NY the...
August 09, 2017 08:00 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two New Patents

BERKELEY, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with three distinct immunotherapy technologies, today announced that the United...
August 03, 2017 16:05 ET | Source: Aduro Biotech, Inc.

Aduro Biotech to Present at the 37th Annual Canaccord Genuity Growth Conference

BERKELEY, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced that Gregory W. Schafer, chief operating officer of Aduro, will present at the 37th Annual...
August 02, 2017 16:01 ET | Source: Aduro Biotech, Inc.

Aduro Biotech Reports Second Quarter 2017 Financial Results

BERKELEY, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today reported financial results for the second quarter of 2017. Net loss for the second quarter 2017 was $19.4...